IQVIA and Medera Partner to Accelerate Cardiac Gene Therapy and Human-Based Drug Discovery

IQVIA and Medera Partner to Accelerate Cardiac Gene Therapy and Human-Based Drug Discovery

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering…

Read MoreIQVIA and Medera Partner to Accelerate Cardiac Gene Therapy and Human-Based Drug Discovery
Neo7Bioscience and McCullough Foundation

Neo7Bioscience and McCullough Foundation Report Findings on Long-Term mRNA Effects and Personalized Peptide Therapies

Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence…

Read MoreNeo7Bioscience and McCullough Foundation Report Findings on Long-Term mRNA Effects and Personalized Peptide Therapies
Estrella

Estrella Immunopharma Adds Third Site for STARLIGHT-1 B-cell Lymphoma Trial

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…

Read MoreEstrella Immunopharma Adds Third Site for STARLIGHT-1 B-cell Lymphoma Trial
Lantern Pharma

Lantern Pharma Spins Off Open-Medicine AI to Advance Multi-Agent AI Co-Scientist Platform

Lantern Pharma Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and…

Read MoreLantern Pharma Spins Off Open-Medicine AI to Advance Multi-Agent AI Co-Scientist Platform
Lōkahi Therapeutics’ ai² Futures Lab™

Lōkahi Therapeutics’ ai² Futures Lab™ Transforms Biopharma Pipeline Development

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline Glucotrack announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45…

Read MoreLōkahi Therapeutics’ ai² Futures Lab™ Transforms Biopharma Pipeline Development
Fresenius

Fresenius Announces FDA and EMA Review Acceptance for Vedolizumab Biosimilar Candidate

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics…

Read MoreFresenius Announces FDA and EMA Review Acceptance for Vedolizumab Biosimilar Candidate
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License…

Read MorePolpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Contineum Therapeutics Reports Q2 2026

Contineum Therapeutics Reports Q2 2026 Financial Results, Reaffirms Key Clinical Development Milestones

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results…

Read MoreContineum Therapeutics Reports Q2 2026 Financial Results, Reaffirms Key Clinical Development Milestones
Feinstein Institutes Scientists Discover the Brain’s Breathing ‘Alarm System’

Feinstein Institutes Scientists Discover the Brain’s Breathing ‘Alarm System’

Feinstein Institutes’ scientists identify the brain’s breathing ‘alarm system’ Beyond automatic breathing reflexes, new research out of Northwell Health’s Feinstein Institutes for Medical Research discovered a brain circuit that keeps track of every inhale and exhale, explaining critical differences in how we perceive,…

Read MoreFeinstein Institutes Scientists Discover the Brain’s Breathing ‘Alarm System’
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

European Commission Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine Across the EU

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Pfizer Inc. and BioNTech SE announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active…

Read MoreEuropean Commission Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine Across the EU
Eastern Technologies Launches COOLGARD Non-Phosphorus Chemistry Line for Industrial Cooling Water

Eastern Technologies Debuts COOLGARD Eco-Friendly Chemistry Line for Industrial Cooling Applications

Eastern Technologies Launches COOLGARD Non-Phosphorus Chemistry Line for Industrial Cooling Water Eastern Technologies, Inc. a Sylmar company and custom formulator of industrial water treatment chemistries, today announced the launch of its COOLGARD Non-Phosphorus product line. The line gives ETI’s partners…

Read MoreEastern Technologies Debuts COOLGARD Eco-Friendly Chemistry Line for Industrial Cooling Applications